Biotech Values

[DewDiligence]

ADXS—USPTO issues CoM patent on ADXS-HER2:

http://finance.yahoo.com/news/advaxis-expands-intellectual-property-lm-130500597.html

The patent expands Advaxis's intellectual property portfolio in claiming numerous compositions for the company's Lm Technology immunotherapy candidate designed to target HER2 expressing cancers. The patent also covers methods of using the same compositions for eliciting an immune response against, preventing the onset of, preventing the formation of, impeding a growth of, preventing an escape mutation in the treatment of, or treating a HER2 expressing tumor.

The patent will expire on September 19, 2032, and also covers ADXS-HER2 use for decreasing the frequency of intra-tumoral T regulatory cells, for decreasing the frequency of myeloid derived suppressor cells, or for increasing intratumoral ratio of CD8+/ T regulatory cells.